News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas
Justin Stebbing/healthpost.in
Jan 29, 2025, 07:24

Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas

Justin Stebbing, Professor of Biomedical Sciences at Anglia Ruskin University (ARU), shared his recent article on LinkedIn:

“Thanks to an amazing team and remarkable drugs, an Fc-enhanced CTLA-4 and anti-PD1, showing an impressive response rate and duration of response in heavily pre-treated sarcoma at Agenus, with special thanks to Robin jones, Breelyn wilky, Joseph grossman and Steven o’day.”

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.

Authors: Breelyn A. Wilky, et al.

Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas

Agenus Anglia Ruskin University ARU Balstilimab botensilimab Breelyn A. Wilky Breelyn Wilky cancer CTLA-4 fight against cancer Global fight against cancer Joseph Grossman Justin Stebbing Metastatic Sarcomas OncoDaily Oncology Robin Jones Steven O'Day
Special Coverage
Science
Jan 29, 2025, 07:24
Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas
Blog
Jan 29, 2025, 06:21
Save the date for 43rd National Conference on Cytometry - AIEOP
Blog
Jan 28, 2025, 20:25
Hung Trinh: Direct in vivo CAR T cell engineering
Career
Jan 28, 2025, 19:39
Nina Bhardwaj - Candidate for the Nominating Committee of AACR
Blog
Jan 28, 2025, 17:24
Sohila Karem: Attending the Cairo BGICC has been an incredibly enriching experience
Science
Jan 28, 2025, 17:24
Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection
Blog
Jan 28, 2025, 17:24
Estela Rodriguez: Dear FDA, clinical trial diversity is not DEI
Blog
Jan 28, 2025, 17:24
Estela Rodriguez: Registration is open for the 22nd Annual PER Winter Lung Cancer Conference
Science
Jan 28, 2025, 17:24
Manel Esteller: Thrilled to introduce our article on mapping the "Hallmarks of Cancer" in human primary tumors
Blog
Jan 28, 2025, 17:23
Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25
Insight
Jan 28, 2025, 17:20
Pashtoon Kasi: Very intriguing to see differences of single agent PD1 vs combination with CTLA4
Blog
Jan 28, 2025, 17:20
Melanoma clinical trial ME17 is officially open for enrollment in Canada - Canadian Cancer Trials Group